Work

Pharmacokinetic/pharmacodynamic analysis of oral amoxicillin-clavulanic acid against extended-spectrum beta-lactamase producing Escherichia coli in an in vitro bladder infection model: impact on clinical breakpoints

Year: 2026
Type: preprint
Abstract: Uropathogens with acquired ESBL-genes can limit effective oral treatment options. Amoxicillin with clavulanic acid can be used as targeted therapy (500/125mg, 8-hourly). Despite favorable urinary pharmacokinetics (PK), there is little urine-specific data that quantifies the exposure required for bacterial clearance. A dynamic in vitro bladder model was employed, allowing for the simulated treatment of UTIs with oral amoxicillin-clavulanic acid. Sixteen Escherichia coli isolates (12 clinical ceftriaxone-resistant uropathogens, 4 laboratory isolates) were selected. Bacterial response to treatment, emergence of resistance, exposure-response targets and PK/PD indexes were explored. Following simulation of standard-dose oral amoxicillin-clavulanic acid (500/125mg, 8-hourly; C max 935mg/L; AUC 0-24 14272mg/L), 14/16 isolates displayed no growth at the end of treatment, with elimination in seven isolates confirmed after a 24h antibiotic-free follow up. As exposure was reduced, greater survival and regrowth were observed. Only two isolates had significant post-exposure rises in MIC (32 to 128mg/L, 64 to 256mg/L). %T >MIC was the best predictor for end of treatment outcome (Δlog 10 cfu/mL: stasis 52.7%, 1log 10 kill 61.8%, 2log 10 kill 71.1%, R 2 =0.9062). Lower R 2 values were found with EUCAST MIC measurements (fixed 2mg/L clavulanic acid) as compared to CLSI MIC measurements (2:1 amoxicillin to clavulanic acid). Monte Carlo simulations indicated that standard-dose 8-hourly would achieve all %T >MIC targets in >95% of virtual patients with MICs ≤64 mg/L, regardless of MIC method (CLSI or EUCAST). Amoxicillin-clavulanic acid displays time-dependent killing against ceftriaxone-resistant E. coli . This data supports clinical breakpoints for uncomplicated UTI for isolates with MIC ≤ 64mg/L, assuming 500/125mg oral dosing 8-hourly.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7234063990
Cites: 62
Cited by:
Related to: 10